Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 10/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14405625 | 1.00 | TRPM8 (0.53) | TRPM8HSD11B1NFE2L2AHRKMT2A | |
| Hydrochloric Acid SCHEMBL15021305 | 0.99 | TRPM8 (0.52) | TRPM8HSD11B1NFE2L2AHRKMT2A | |
| Hydrochloric Acid SCHEMBL15021302 | 0.99 | TRPM8 (0.52) | TRPM8HSD11B1NFE2L2AHRKMT2A | |
| SCHEMBL15023793 | 0.86 | TRPM8 (0.53) | TRPM8 | |
| SCHEMBL14407053 | 0.86 | TRPM8 (0.53) | TRPM8 | |
| SCHEMBL14405541 | 0.85 | TRPM8 (0.45) | TRPM8NFE2L2CLK4 | |
| SCHEMBL15021787 | 0.85 | TRPM8 (0.45) | TRPM8NFE2L2CLK4 | |
| SCHEMBL15963687 | 0.85 | TRPM8 (0.40) | TRPM8MAOB | |
| SCHEMBL14406986 | 0.84 | TRPM8 (0.50) | TRPM8HSD11B1 | |
| SCHEMBL14406977 | 0.84 | TRPM8 (0.50) | TRPM8HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710043-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | TRPM8 1/4885HSD11B1 4726/4885NFE2L2 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.